We are live on ! Find out more

AngioDynamics

ANGO

Market cap $655M

15.85 USD

+0.07

0.44%

At close Updated Aug 28, 4:00 PM EDT

1 day

0.44%

5 days

0.76%

1 month

10.53%

3 months

34.44%

6 months

39.52%

Year to date

25%

1 year

56.47%

5 years

-44.37%

10 years

-5.82%

About: AngioDynamics Inc is a dynamic, diversified medical technology company committed to expanding treatment options and improving patient outcomes and quality of life by designing, manufacturing, and selling products and technologies that aid clinicians in the treatment of patients with cardiovascular disease and cancer diagnoses. The company's execution plan is built on R&D, clinical and regulatory pathway expansion, and customer-centric sales performance. The company's product offerings fall within two segments, Med Tech and Med Device. Med Tech includes Auryon and Thrombectomy, while Med Device has Peripheral Products (Interventional Devices), Ports, and Microwave Ablation. Geographically operates in the USA and Other countries; maximum revenue from the USA.

Employees: 632

Healthcare Medical Instruments & Supplies

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 35.3%

Neutral 58.8%

Negative 5.9%

Zacks Investment Research

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock?

AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

AngioDynamics NASDAQ: ANGO expects its MedTech business to become the majority of company revenue in fiscal 2027, as the company continues a multiyear shift away from slower-growth legacy markets and toward higher-growth medical technology platforms, executives said during a Canaccord fireside chat.

AngioDynamics Sees MedTech Becoming Majority of Revenue in Fiscal 2027

Zacks Investment Research

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

AngioDynamics' Med Tech growth and reimbursement gains strengthen its outlook, but tariffs, rising costs and execution risks keep the buy case uncertain.

Is ANGO a Buy as Med Tech Growth Battles Persistent Margin Pressure?

Zacks Investment Research

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

AngioDynamics' fiscal 2027 outlook hinges on Med Tech growth offsetting flat device sales as tariffs, spending and losses pressure margins.

ANGO's FY27 Guidance Puts Med Tech Growth and Tariff Risks in Focus

Zacks Investment Research

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

AngioDynamics' 33.5% three-month rally rests on Med Tech growth, but valuation, tariffs and negative earnings keep execution risks high.

ANGO Jumps 33.5% in 3 Months: Can the Rally Keep Going?

AngioDynamics to Participate in Upcoming Investor Conferences

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that its management team is scheduled to participate in the following upcoming investor conferences: 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference Monday, August 10, 2026 Canaccord Genuity's 4.

AngioDynamics to Participate in Upcoming Investor Conferences

AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

AngioDynamics develops tools for minimally invasive procedures across blood flow, blocked arteries, and prostate cancer treatment. Key offerings include AlphaVac and AngioVac for clot removal, Auryon for arterial plaque, and NanoKnife for prostate cancer. After a prolonged period of stagnation, ANGO shares are finally showing signs of positive momentum.

AngioDynamics: Growth Is Working, Price Knows It (Rating Downgrade)

Zacks Investment Research

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.

AngioDynamics Q4 Earnings Beat Estimates, Gross Margin Expands

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q4 2026 Earnings Call Transcript

AngioDynamics Q4 Earnings Call Highlights

AngioDynamics NASDAQ: ANGO reported higher fiscal fourth-quarter and full-year revenue, driven by continued growth in its med tech portfolio, while management said the company remains focused on balancing investment in clinical programs with profitability and cash generation.

AngioDynamics Q4 Earnings Call Highlights

See News Rankings

Price charts implemented using Lightweight Charts™